Originally published as JCO Early Release 10.1200/JCO.2006.09.4532 on May 14 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rose, P. G. Articles by Insalaco, S. Search for Related Content PubMed PubMed Citation Articles by Rose, P. G. Articles by Insalaco, S. Social Bookmarking                            What's this?

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study

Peter G. Rose, Shamshad Ali, Edwin Watkins, J. Tate Thigpen, Gunter Deppe, Daniel L. Clarke-Pearson, Samuel Insalaco

From Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Columbus Regional Hospital, Columbus, IN; University of Mississippi Medical Center, Jackson, MS; Wayne State University/Karmanos Cancer Institute, Detroit, MI; University of North Carolina, Chapel Hill, NC; and the Tacoma General Hospital, Tacoma, WA

Address reprint requests to Peter G. Rose, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: rosep{at}ccf.org

Purpose We report the long-term survival and toxicity of a randomized phase III study comparing cisplatin alone with cisplatin, flurouracil, and hydroxyurea versus hydroxyurea concurrent with pelvic irradiation for patients with locally advanced cervical cancer with pathologically negative para-aortic nodes.

Patients and Methods Comparisons of progression-free (PFS) and overall survival (OS) between treatment arms utilized Kaplan-Meier and log-rank statistics. Relative risk estimates adjusting for prognostic factors were determined using the Cox proportional hazards regression model. Pearson's ² test was used to assess differences in adverse events.

Results The analysis included 526 patients. The median follow-up among surviving patients was 106 months. Consistent with the original report, improvement in PFS and OS was evident for both cisplatin-containing arms compared with hydroxyurea (P < .001). Analogous results were seen for stage IIB and for stage III disease (each P < .025). The relative risk of progression of disease or death was 0.57 (95% CI, 0.43 to 0.75) with cisplatin and 0.51 (95% CI, 0.38 to 0.67) with cisplatin-based combination chemotherapy compared with hydroxyurea. Among 518 patients who received radiation, acute (grade 3 or 4) gastrointestinal or urologic toxicities occurred in 66 with cisplatin (19.1%) and 29 with hydroxyurea (16.8%). Delayed radiation toxicity occurred in six patients who received cisplatin (1.7%) and two who received hydroxyurea (1.2%; P = .680).

Conclusion Cisplatin-based chemotherapy during pelvic radiation therapy improves long-term PFS and OS among locally advanced cervical cancer patients collectively and for stage IIB and III disease, individually. There was no observed increase in late toxicity with cisplatin-based chemoradiotherapy.

published online ahead of print at www.jco.org on May 14, 2007.

Supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and to the Gynecologic Oncology Group Statistical and Data Center (CA 37517) and by Amgen.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?